Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 6

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 6
---
 Stock issuable upon the exercise of common warrants to purchase shares of Common Stock (the “October 2024 Common Warrants”) purchased by institutional investors (the “October 2024 Investors” and, together with the March 2024 Investors and the August 2024 Investor, the “Investors”) in a private placement transaction (the “October 2024 Private Placement”) pursuant to the terms of a securities purchase agreement dated as of October 18, 2024 (the “October 2024 Purchase Agreement”) between us and the October 2024 Investors; and (ii) 61,448 shares of Common Stock issuable upon the exercise of warrants (the “October 2024 PA Warrants” and, together with the October 2024 Common Warrants, the “October 2024 Warrants”) to purchase shares of Common Stock issued to designees of WallachBeth as partial compensation for WallachBeth acting as placement agent in connection with the October 2024 Private Placement. The October 2024 Private Placement closed on October 21, 2024. As of June 27, 2025, October 2024 Warrants to purchase 1,526,391 shares of Common Stock remain outstanding and unexercised and 260,000 shares of Common Stock that were issued upon exercise of October 2024 Common Warrants continue to be held by certain of the selling stockholders identified in the December 2024 Registration Statement.

The March 2024Investors, August 2024 Investors, October 2024 Investors and the designees of WallachBeth are sometimes hereinafter collectively referred to as the “Selling Stockholders.” The March 2024 Warrants, the August 2024 Warrants and the October 2024 Warrants are sometimes hereinafter collectively referred to as the “Common Warrants.” The shares of Common Stock issuable upon exercise of the Common Warrants are referred to as the “Common Warrant Shares.”

This prospectus relates to the resale by the Selling Stockholders of up to: (i) 565,333 shares of Common Stock issuable upon exercise of outstanding March 2024 Warrants; (ii) 499,862 shares of Common Stock issuable upon exercise of outstanding August 2024 Warrants; (iii) 1,526,391 shares of Common Stock issuable upon exercise of outstanding October 2024 Warrants and (iv) 260,000 shares of Common Stock that were previously issued upon the